Sanofi SA (SNY) Shares Sold by Wetherby Asset Management Inc.
Wetherby Asset Management Inc. trimmed its holdings in shares of Sanofi SA (NYSE:SNY) by 1.2% during the first quarter, HoldingsChannel.com reports. The firm owned 35,548 shares of the company’s stock after selling 440 shares during the quarter. Wetherby Asset Management Inc.’s holdings in Sanofi were worth $1,574,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of SNY. Essex Savings Bank purchased a new stake in Sanofi in the 4th quarter worth about $30,000. Claybrook Capital LLC purchased a new stake in Sanofi in the 4th quarter worth about $31,000. Executive Wealth Management LLC purchased a new stake in Sanofi in the 4th quarter worth about $34,000. Nkcfo LLC purchased a new stake in Sanofi in the 1st quarter worth about $35,000. Finally, Cullen Frost Bankers Inc. purchased a new stake in Sanofi in the 1st quarter worth about $35,000. 7.04% of the stock is currently owned by institutional investors.
Shares of SNY traded down $0.03 during midday trading on Friday, reaching $42.08. 15,716 shares of the stock were exchanged, compared to its average volume of 1,025,278. Sanofi SA has a 12-month low of $37.67 and a 12-month high of $45.62. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The company has a market capitalization of $105.49 billion, a PE ratio of 13.44, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.
The company also recently declared an annual dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 8th will be paid a dividend of $1.7395 per share. This represents a dividend yield of 4.2%. The ex-dividend date of this dividend is Tuesday, May 7th. Sanofi’s dividend payout ratio (DPR) is presently 37.38%.
In related news, major shareholder Sanofi sold 131,115 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total value of $54,041,669.55. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by company insiders.
A number of equities research analysts have recently weighed in on the company. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $48.00 price target for the company in a research note on Monday, February 4th. HC Wainwright reaffirmed a “buy” rating on shares of Sanofi in a research note on Thursday, February 28th. Finally, TheStreet downgraded Sanofi from a “b” rating to a “c+” rating in a research note on Thursday, February 7th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $51.00.
COPYRIGHT VIOLATION NOTICE: “Sanofi SA (SNY) Shares Sold by Wetherby Asset Management Inc.” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/sanofi-sa-sny-shares-sold-by-wetherby-asset-management-inc/3021159.html.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Featured Story: What are the Benefits of Index Funds?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.